Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 148 от 222

Набира участници Фаза 2

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate medical problems. An endoscopy will be used to check the bowel for inflammation. The participants will be treated with TAK-279 for 52 weeks (1 year). During the study, participants will visit their study clinic 15 times.

Начало: 05.03.2024 Край: 23.07.2027 Възраст: 18–75 г. Лечение

Australia, Belgium, Brazil +21 Takeda NCT06233461

Набира участници Фаза 3

A Study of Sepiapterin in Participants With Phenylketonuria (PKU)

Phenylketonuria

The main purpose of this trial is to evaluate the long-term efficacy of sepiapterin on preserving neurocognitive functioning in children with PKU when treatment is initiated in early childhood.

Начало: 04.03.2024 Край: 28.02.2031 Възраст: до 10 г. Лечение

Australia, Poland, United Kingdom +1 PTC Therapeutics NCT06302348

Набира участници Фаза 1/2

Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy

Myotonic Dystrophy 1

This is a phase 1/2a double-blinded, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending doses of ARO-DM1 compared to placebo in male and female subjects with type 1 myotonic dystrophy (DM1). Participants who have provided written informed consent and met all protocol eligibility requirements will be randomized to receive single (Part 1) or multiple (Part 2) doses of ARO-DM1 or placebo.

Начало: 04.03.2024 Край: 01.12.2026 Възраст: 18–65 г. Лечение

Australia, New Zealand, Taiwan +1 Arrowhead Pharmaceuticals NCT06138743

Набира участници

Evaluation of the MAGNITUDE® Bioresorbable Drug-Eluting Scaffold in the Treatment of Patients With Below the Knee Disease in Australia

Critical Limb-Threatening Ischemia Critical Limb Ischemia Critical Lower Limb Ischemia

The objective of this prospective, multi-center, clinical investigation is to evaluate the MAGNITUDE BRS System for the planned treatment of narrowed infrapopliteal lesions. Up to 30 subjects will be enrolled at approximately 3 clinical sites in Australia.

Начало: 04.03.2024 Край: 31.12.2030 Възраст: от 18 г. Лечение

Australia R3 Vascular Inc. NCT06075940

Набира участници Фаза 4

The STOP-MED CTRCD Trial

Heart Failure Cardiotoxicity Cardiac Toxicity Antineoplastics Toxicity +1

Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients. When this occurs, heart failure medications are started to protect the heart from progressing to heart failure. With early detection and treatment, heart function recovers to normal in \>80% of patients. Unfortunately, heart failure medications are associated with an undesirable long-term pill burden, financial costs, and side-effects (e.g., dizziness and fatigue). As a result, cancer survivors frequently ask if they can safely stop their heart failure medications once their heart function has returned to normal. Currently there is no scientific evidence in this area of Cardio-Oncology. To address this knowledge gap, the investigators have designed a randomized control trial to assess the safety of stopping heart failure medication in patients with CTRCD and recovered heart function. The investigators will enrol patients who have completed their cancer therapy and are on heart medications for their CTRCD, which has now normalized. The investigators will randomize patients with no other reasons to continue heart failure medications (e.g., kidney disease) to continuing or stopping their heart medications safely. All patients will undergo a cardiac MRI at baseline, 1 and 5 years with safety assessments at 6-8 weeks, 6 months and 3 and 5 years. The investigators will determine if stopping medications is non-inferior to continuing medications by counting the numbers of patients who develop heart dysfunction by 1 year in each group.

Начало: 04.03.2024 Край: 01.12.2031 Възраст: от 18 г. Лечение

Australia, Canada, Poland +3 Dinesh Thavendiranathan NCT06183437

Набира участници Фаза 2

A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD

Graft Versus Host Disease, Acute

This study is a prospective randomized placebo-controlled phase 2 study to compare CYP-001 plus corticosteroids (CS) to placebo plus CS in allogeneic hematologic stem cell transplant recipients with HR-aGvHD. Severity of GvHD will be assessed at screening and throughout the study using Mount Sinai Acute GvHD International Consortium (MAGIC) guidelines. Eligible subjects will be randomized to receive either CYP-001 IV infusion on Days 0 and 4 or placebo on the same days. All subjects will receive ongoing CS therapy as appropriate per institutional guidelines. Subjects will have study visits up to Day 100 during the Primary Evaluation Period. During the Follow-Up Period, subjects will have study visits up to 24 months.

Начало: 04.03.2024 Край: 01.12.2027 Възраст: от 18 г. Лечение

Australia, France, Italy +4 Cynata Therapeutics Limited NCT05643638

Набира участници

Assessing the Efficacy and Safety of ctDNA-driven Selection for Anti-EGFR Retreatment in a Real World Metastatic Colorectal Cancer Patients Cohort (the REalCHALLENGE Study)

Metastatic Colorectal Cancer (CRC)

This is an observational, retrospective, international and multicenter study funded by Fondazione Oncologia Niguarda ETS to assess the efficacy of anti-EGFR rechallenge regimens in the largest real-world cohort of MSS mCRC patients screened for RAS/BRAF/PIK3CA ctDNA status on liquid biopsy within the MEN1611-02 C-PRECISE-01 trial. The study will collect molecular, clinical and outcome data of patients already available at participating centers.

Начало: 01.03.2024 Край: 01.09.2026 Възраст: от 18 г.

Italy Niguarda Hospital NCT07536113

Набира участници

Laser Treatment for Lichen Sclerosus

Lichen Sclerosus Lesion

Fractional ablative laser treatment for Lichen Sclerosus lesion

Начало: 01.03.2024 Край: 30.12.2027 Възраст: от 18 г.

Canada Sciton NCT06389071

Набира участници

Motivations, Attitudes, and Perceptions Study

Alcohol Drinking Sexual Violence Social Norms

The goal of this clinical trial is to compare the impact of providing participants with 1. A recently developed protocol for motivating bystanders to intervene to help others who are in sexual risk situations (Motivate-the-Bystander) alone 2. Motivate-the-Bystander with an alcohol component focused on reducing drinking behaviors (Motivate-the-Bystander+Alcohol) 3. A control condition focused on reducing stress The main questions it aims to answer are: * Is Motivate-the-Bystander more effective than the attention control for increasing bystander behaviors? * Is Motivate-the-Bystander+Alcohol more effective than MTB alone for increasing bystander behaviors? * Is Motivate-the-Bystander+Alcohol more effective than Motivate-the-Bystander alone for decreasing alcohol use during bystander intervention opportunities? Participants will: * Complete online measures (e.g., self-reported bystander behaviors, past bystander training, history of bystander intervention attempts, sexual experiences, drinking behaviors, and other substance use behaviors) * Complete either MTB, MTB+ALC, or the attention control condition online * Complete the virtual reality simulation in the lab * Complete electronic daily diary follow-up surveys about alcohol use and bystander intervention

Начало: 01.03.2024 Край: 31.05.2026 Възраст: 18–25 г.

United States University of Nebraska Lincoln NCT05873413

Набира участници Фаза 2

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

C3 Glomerulopathy Idiopathic Immune Complex-Mediated Glomerulonephritis

The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of OMS906 in patients with C3 Glomerulopathy (C3G) and Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN)

Начало: 01.03.2024 Край: 01.04.2026 Възраст: 18–99 г. Лечение

Lithuania, New Zealand, Poland +1 Omeros Corporation NCT06209736

Набира участници

Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis

Degenerative Disc Disease Spondylolisthesis

The objective of this clinical study is to evaluate the safety and effectiveness of NB1 Bone Graft in subjects with degenerative disc disease undergoing transforaminal lumbar interbody fusion. It is estimated that up to 30 participants will be enrolled in approximately 3 clinical sites. During baseline and follow-up assessments, patients will be asked to undergo x-rays and CT scans; adverse events and immunology will be collected, and; participants will be requested to complete participant questionnaires regarding quality of life, pain and function.

Начало: 01.03.2024 Край: 01.06.2026 Възраст: 17–70 г. Лечение

Australia Bone Biologics Corp NCT03810573

Набира участници

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

Breast Cancer Cognitive Impairments

This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.

Начало: 29.02.2024 Край: 30.11.2027 Възраст: 18–100 г.

Puerto Rico, United States NRG Oncology NCT05896189

Набира участници Фаза 3

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

Dermatitis Atopic

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and older on background TCS and have had an inadequate response to prior biologic or an oral JAKi therapy. Study details include: At the end of the treatment period, participants will have the option to enter the Long-Term Safety Study LTS17367 (RIVER-AD). The study duration will be up to 56 weeks for participants not entering the long-term safety study (LTS17367 \[RIVER-AD\]) including a 2 to 4-week screening, a 36-week randomized double-blind period, and a 16-week safety follow-up. The study duration will be up to 40 weeks for participants entering the long-term safety study (LTS17367 \[RIVER-AD\]) including a 2 to 4-week screening and a 36-week randomized double-blind period. The total treatment duration will be up to 36 weeks. The total number of visits will be up to 13 visits (or 12 visits for those entering the long-term safety study LTS17367 \[RIVER-AD\] study).

Начало: 29.02.2024 Край: 14.09.2026 Възраст: от 12 г. Лечение

Argentina, Australia, Brazil +20 Sanofi NCT06241118

Набира участници

Comparison of Residual Gastric Volume Between Children Who Drink Different Clear Oral Fluid Volume

Fasting Gastric Emptying

According to the American Society of Anesthesiologists (ASA) fasting guideline for patients undergoing elective surgery, the 2-hour fasting period is suggested for clear oral fluid (including water, pulp-free juice and tea or coffee without milk). This guideline does not give any suggestions for proper volume of clear oral fluid intake. This study is a prospective randomized control trials in children aged 13 through 17 years who are scheduled for an elective upper GI endoscopy procedure in the Gastroenteral Procedure Unit (GPU) at Boston Children's Hospital. The participants will be randomly assigned into one of four groups: Group 1 will consume 3 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time, Group 2 will consume 5 ml/kg, Group 3 will consume 7 ml/kg, and Group 4 will consume 10 ml/kg. The investigators plan to recruit 72 patients in each group and 288 patients for the whole study. Research team will collect patient's demographic data, vital signs, information about their EGD procedure. Then actual volume of the stomach content and acidity will be measured from the content that is suctioned from patient's stomach during upper GI endoscopy procedure. The investigators believe that the information from this study will help establish a comprehensive NPO guideline.

Начало: 29.02.2024 Край: 01.12.2027 Възраст: 13–17 г.

United States Boston Children's Hospital NCT03741777

Набира участници Фаза 3

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Early Breast Cancer

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC).

Начало: 28.02.2024 Край: 20.09.2030 Възраст: 18–100 г. Лечение

Argentina, Australia, Brazil +13 Novartis Pharmaceuticals NCT05827081

Набира участници Фаза 2/3

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Solid Cancer

This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.

Начало: 27.02.2024 Край: 30.04.2030 Възраст: от 18 г. Лечение

Australia, Canada, China +11 Daiichi Sankyo NCT06161025

Набира участници

PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients

Coronary Artery Disease

Post-market, prospective, observational, multicenter, non-intervention study, to demonstrate the effectiveness of drug-coated ballon (DCB)therapy in real-world patients with small native vessel coronary artery disease, and to demonstrate the safety of short dual antiplatelet therapy (7 days) in high-bleeding risk patients with native small vessel coronary artery disease treated with DCB therapy. A percutaneous coronary intervention (PCI) with DCB will be performed in patients with native vessel coronary artery disease based on the criterion of the treating physician.

Начало: 26.02.2024 Край: 30.12.2026 Възраст: от 18 г.

Italy, Portugal, Spain Fundación EPIC NCT06321757

Набира участници Фаза 2

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumor Melanoma Head and Neck Cancer Gastric Cancer +10

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric cancer ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, prostate cancer, second-line gastric cancer, lung cancer, and breast cancer.

Начало: 26.02.2024 Край: 10.10.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +13 Daiichi Sankyo NCT06172478

Набира участници

Association Between LRG and Histologic Remission in Ulcerative Colitis

Ulcerative Colitis in Histologic Remission

We attempt to clarify the serum leucine-rich α 2-glycoprotein (LRG) level which can predict histologic remission in ulcerative colitis patients in this study. Colonoscopy with histology will be performed when histologic remission is predicted, irrespective of symptoms or serum LRG values. Serum LRG levels are analyzed by an enzyme-linked immunosorbent assay.

Начало: 25.02.2024 Край: 31.12.2027 Възраст: 20–90 г.

Japan Showa Inan General Hospital NCT06372613

Набира участници Фаза 2

Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)

Obsessive-Compulsive Disorder

The purpose of this study is to understand how ketamine works in the brain to bring about a reduction in OCD symptoms.

Начало: 24.02.2024 Край: 01.11.2028 Възраст: 18–65 г.

United States Stanford University NCT05940324

1 … 146 147 148 149 150 … 222